Diazoles (including Hydrogenated) Patents (Class 514/94)
-
Publication number: 20070213302Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.Type: ApplicationFiled: March 9, 2007Publication date: September 13, 2007Applicant: JENRIN DISCOVERYInventors: John Francis McElroy, Robert J. Chorvat
-
Patent number: 7235666Abstract: Phosphoric acid diester 2,5-dioxo-4,4-diphenylimidazolidin-1-ylmethyl esters, both of whose ester groups can be selectively cleaved, are obtained by converting 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione to an alkylsulfonate or arylsulfonate and reacting this with a phosphoric acid diester whose ester groups can be selectively cleaved from the reaction product. The two ester groups can be selectively cleaved from the phosphoric acid diesters obtained and the resulting product can be converted to 5,5-diphenyl-3-[(phosphonooxy)methyl]imidazolidine-2,4-dione disodium salt. The latter is an anticonvulsive, antiepileptic and antiarrhythmic known under the abbreviated name of sodium fosphenytoin.Type: GrantFiled: May 31, 2005Date of Patent: June 26, 2007Assignee: Cilag Ltd.Inventor: Volker Kirsch
-
Patent number: 7217704Abstract: The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.Type: GrantFiled: October 12, 2004Date of Patent: May 15, 2007Assignee: The University of Tennessee Research FoundationInventors: Duane D. Miller, Gabor Tigyi, Gangadhar G. Durgam, Tamas Virag, Michelle D. Walker, Ryoko Tsukahara
-
Patent number: 7208481Abstract: The present invention relates to methods of use of aminodiphosphonate to modulate apolipoprotein E levels and the use of such compounds in therapy, including cardiovascular and neurological disease states.Type: GrantFiled: February 14, 2003Date of Patent: April 24, 2007Assignee: ILEX Products, Inc.Inventors: Hieu Trung Phan, Lân Mong Nguyen, Raymond Azoulay, Vinh Van Diep, Eric Joseph Niesor, Craig Leigh Bentzen, Yves Gyon Gellin, Anne Perez, Jean-Luc Thulliard
-
Patent number: 7105556Abstract: Compounds are provided which have the structure wherein Q is C or N, X1 is C or N, and R1, R2, R2a, R2b, R2c, R3, Y, A, m, n, X2, X3 and X4 are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.Type: GrantFiled: May 22, 2002Date of Patent: September 12, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Peter T. Cheng, Yoon Jeon, Wei Wang
-
Patent number: 7030103Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: October 8, 2002Date of Patent: April 18, 2006Assignee: Methylgene, Inc.Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
-
Patent number: 6965033Abstract: Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.Type: GrantFiled: December 22, 2000Date of Patent: November 15, 2005Assignee: Metabasis Therapeutics, Inc.Inventors: Tao Jiang, Srinivas Rao Kasibhatla, K. Raja Reddy
-
Patent number: 6919322Abstract: Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.Type: GrantFiled: March 7, 2001Date of Patent: July 19, 2005Assignee: Metabasis Therapeutics, Inc.Inventors: Brett C. Bookser, Qun Dang, K. Raja Reddy
-
Publication number: 20040157915Abstract: Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. Also provided are compositions and methods for combination therapy employing ileal bile acid transport inhibitors and HMG Co-A reductase inhibitors for the treatment of hyperlipidemic conditions.Type: ApplicationFiled: July 17, 2003Publication date: August 12, 2004Applicant: G.D. Searle & Co.Inventors: Bradley T. Keller, Kevin C. Glenn, Robert E. Manning
-
Patent number: 6762227Abstract: The use of an aromatic compound substituted with at least one heterocyclic amine and possibly additional substituents, such as medetomidine and clonidine, or a functionally analogous derivative thereof, as an agent for the inhibition of marine biofouling on a surface, by application thereon of said compound, is disclosed. Also a method for inhibition of marine biofouling on a surface by application of said compound is disclosed.Type: GrantFiled: November 27, 2001Date of Patent: July 13, 2004Assignee: I-Tech ABInventors: Hans Elwing, Lena Mårtensson
-
Patent number: 6756391Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: May 9, 2002Date of Patent: June 29, 2004Assignee: AnorMed, Inc.Inventors: Gary James Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Tony Skerlj, David Earl Bogucki
-
Patent number: 6703368Abstract: This invention relates to peptide-containing &agr;-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same.Type: GrantFiled: June 12, 2001Date of Patent: March 9, 2004Assignee: Cephalon, Inc.Inventors: Sankar Chatterjee, John P. Mallamo, Ron Bihovsky, Gregory J. Wells
-
Publication number: 20040029943Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.Type: ApplicationFiled: August 4, 2003Publication date: February 12, 2004Inventors: Yajing Rong, Jack B. Jiang, Syed M. Ali
-
Publication number: 20040023929Abstract: The present invention provides a compound and a method of making a compound according to the following formula: 1Type: ApplicationFiled: May 5, 2003Publication date: February 5, 2004Inventors: Richard S. Larson, Carston R. Wagner
-
Publication number: 20040014724Abstract: A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.Type: ApplicationFiled: January 21, 2003Publication date: January 22, 2004Inventors: John J. Seaman, Bruno Galli, Horst F. Schran
-
Publication number: 20030232790Abstract: The present invention provides dihydro-2H-napthalene-1-ones of formula (V), and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.Type: ApplicationFiled: October 8, 2002Publication date: December 18, 2003Inventors: Daniele Marie Leonard, Joseph Thomas Repine, Gordon William Rewcastle
-
Publication number: 20030195171Abstract: Composition and method for preventing or treating abnormal bone resorption in mammals, the composition characterized as containing, a supplementary effective amount of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of bisphosphonate to provide vitamin D nutrition during treatment to facilitate normal bone formation and mineralization, while minimizing the occurrence of or potential for the complications associated with vitamin D insufficiency, such as hypocalcemia and osteomalacia. The method of preventing or treating may be further characterized by concomitantly administering the components simultaneously or alternately at dosing intervals selected from once-weekly, twice-weekly, bi-weekly, monthly, and bi-monthly.Type: ApplicationFiled: April 1, 2003Publication date: October 16, 2003Inventors: Anastasia G. Daifotis, Sidney Mazel, John Yates
-
Publication number: 20030181421Abstract: Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, wherein the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.Type: ApplicationFiled: March 25, 2003Publication date: September 25, 2003Inventors: Zebulun D. Horowitz, Peter C. Richardson, Ulrich Trechsel
-
Publication number: 20030176403Abstract: The invention provides a method of treating a patient with vitamin-D or a derivative thereof involving the adjunctive administration of zoledronate.Type: ApplicationFiled: March 17, 2003Publication date: September 18, 2003Applicant: University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Candace S. Johnson, Donald J. Trump
-
Publication number: 20030144251Abstract: The invention relates to novel 1-arylpyrazole oxime derivatives, of general formula (I) or (I bis) 1Type: ApplicationFiled: July 18, 2002Publication date: July 31, 2003Applicant: Rhone-Poulenc Inc.Inventors: Tai-Teh Wu, Alain Chene, David Treadway Manning, Peter Wyatt Newsome, Nicholas Charles Ray, Jennifer Lantz Phillips, Patrick Doyle Lowder
-
Publication number: 20030129177Abstract: A dietary supplement is disclosed which supplies the skeletal muscle with energy and protects the cardiovascular tract, the characterising components of which comprise propionyl L-carnitine, coenzyme Q10, nicotinamide, riboflavin and pantothenic acid.Type: ApplicationFiled: January 14, 2003Publication date: July 10, 2003Applicant: Sigma-Tau HealthScience S.p.A.Inventor: Franco Gaetani
-
Publication number: 20030064966Abstract: The present invention relates to the treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form. The invention also relates to pharmaceutical inhalation compositions suitable for the treatment and prevention of bone diseases.Type: ApplicationFiled: May 17, 2002Publication date: April 3, 2003Inventor: Nageswara R. Palepu
-
Publication number: 20030060453Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.Type: ApplicationFiled: February 15, 2002Publication date: March 27, 2003Inventors: Zaihui Zhang, Timothy Scott Daynard, Serguei V. Sviridov, Mikhail A. Chafeev, Shisen Wang
-
Publication number: 20030050285Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of hemorrhagic stroke.Type: ApplicationFiled: September 19, 2002Publication date: March 13, 2003Applicant: SmithKline Beecham p.l.c.Inventor: James Hill
-
Patent number: 6514952Abstract: Compounds of the formula I in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I, and of pharmaceutical preparations which contain such compounds, for the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell—cell or cell-matrix interactions play a part which are based on interactions of VLA-4 receptors with their ligands, for example of inflammatory processes, rheumatoid arthritis or allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.Type: GrantFiled: September 27, 1999Date of Patent: February 4, 2003Assignee: Hoechst AktiengesellschaftInventors: Hans Ulrich Stilz, Volkmar Wehner, Christoph Huels, Dirk Seiffge
-
Patent number: 6500811Abstract: Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved.Type: GrantFiled: March 20, 2001Date of Patent: December 31, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Manfred Schudok, Wilfried Schwab, Gerhard Zoller, Eckart Bartnik, Frank Büttner, Klaus-Ulrich Weithmann
-
Patent number: 6498151Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.Type: GrantFiled: March 21, 2001Date of Patent: December 24, 2002Assignee: Merck Frosst Canada & Co.Inventors: Chun Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
-
Patent number: 6492410Abstract: Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.Type: GrantFiled: November 6, 2000Date of Patent: December 10, 2002Assignee: Warner-Lambert CompanyInventors: Judith Leopold, Roger Schofield Newton
-
Publication number: 20020173492Abstract: Compounds of formula (I) or pesticidally acceptable salts thereof, compositions containing them and methods of use.Type: ApplicationFiled: February 1, 2002Publication date: November 21, 2002Inventor: Tai-Teh Wu
-
Publication number: 20020160988Abstract: Chimeric compounds are disclosed which are covalent conjugates of reversible or irreversible cholinergic up-regulators and non-steroidal anti-inflammatory drugs (NSAIDs), methods for their synthesis and use thereof for treatment and/or prevention of central nervous system (CNS) disorders and diseases.Type: ApplicationFiled: July 16, 2001Publication date: October 31, 2002Applicant: Israel Institute for Biological ResearchInventors: Gabriel Amitai, Rachel Adani, Ishai Rabinovitz, Gali Sod-Moriah, Haim Meshulam
-
Publication number: 20020160985Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for primary and secondary prevention of infarction.Type: ApplicationFiled: April 29, 2002Publication date: October 31, 2002Applicant: SmithKline Beecham plcInventor: James Hill
-
Publication number: 20020132794Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.Type: ApplicationFiled: February 13, 2002Publication date: September 19, 2002Applicant: MEDIVIR ABInventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky
-
Publication number: 20020115702Abstract: The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2′-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.Type: ApplicationFiled: February 19, 2002Publication date: August 22, 2002Applicant: MERCK SHARP & DOHME (Italia) S.p.A.Inventor: Giuseppe Remuzzi
-
Patent number: 6425881Abstract: Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.Type: GrantFiled: April 16, 1999Date of Patent: July 30, 2002Assignee: Nitrosystems, Inc.Inventor: Wayne H. Kaesemeyer
-
Publication number: 20020091104Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.Type: ApplicationFiled: March 21, 2001Publication date: July 11, 2002Inventors: Chung Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
-
Publication number: 20020072507Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.Type: ApplicationFiled: September 11, 2001Publication date: June 13, 2002Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
-
Publication number: 20020055490Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for improving cognitive function.Type: ApplicationFiled: February 27, 2001Publication date: May 9, 2002Applicant: SmithKline Beecham p.l.c.Inventor: James Hill
-
Publication number: 20020042400Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.Type: ApplicationFiled: August 15, 2001Publication date: April 11, 2002Inventors: Yajing Rong, Jack B. Jiang, Ali M. Syed
-
Patent number: 6352985Abstract: A benzimidazole compound represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.Type: GrantFiled: January 28, 2000Date of Patent: March 5, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Yoshiyuki Murai, Takahiro Hiramura, Teruo Oku, Kouzou Sawada
-
Publication number: 20020013295Abstract: The present invention relates to pharmaceutical compositions and methods for treating amyotrophic lateral sclerosis using NAALADase inhibitors.Type: ApplicationFiled: May 30, 2001Publication date: January 31, 2002Inventors: Barbara S. Slusher, Krystyna Wozniak
-
Publication number: 20020004594Abstract: Novel phosphoramidate derivatives of hydroxy functional or amino functional compounds, including amino acids, peptides, peptidomimetics and nucleotide analogs, are described. The compounds enable enhanced intracellular delivery of drugs as their corresponding phosphate esters or amides. Described phosphoramidate compounds exhibit antiproliferative activity. Pharmaceutical formulations are provided for treatment of cancers.Type: ApplicationFiled: March 30, 2001Publication date: January 10, 2002Inventors: Richard F. Borch, Hugo Garrido-Hernandez, Sandra C. Tobias
-
Publication number: 20020004495Abstract: The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.Type: ApplicationFiled: July 3, 2001Publication date: January 10, 2002Inventors: Shun-Ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc Labelle, Kathleen Metters, Robert N. Young, Miron Weinreb
-
Publication number: 20010051615Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of angina.Type: ApplicationFiled: July 19, 2001Publication date: December 13, 2001Applicant: SmithKline Beecham p.l.c.Inventor: James Hill
-
Publication number: 20010041691Abstract: Water-soluble prodrugs of triazole antifungal compounds having a secondary or tertiary hydroxy group are provided.Type: ApplicationFiled: January 10, 2001Publication date: November 15, 2001Inventors: Yasutsugu Ueda, John D. Matiskella, Jerzy Golik, Thomas W. Hudyma, Chung-Pin Chen
-
Patent number: 6300501Abstract: Inhibitors of protein farnesyl transferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.Type: GrantFiled: November 2, 1998Date of Patent: October 9, 2001Assignee: Warner-Lambert CompanyInventors: Ellen M. Dobrusin, Annette M. Doherty, James S. Kaltenbronn, Daniele M. Leonard, Dennis J. McNamara, Judith Sebolt-Leopold, Kevon R. Shuler
-
Patent number: 6300356Abstract: Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in die risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.Type: GrantFiled: August 10, 2000Date of Patent: October 9, 2001Assignee: Merck & Co., Inc.Inventors: Robert Segal, Paul J. Robinson, Lawrence I. Deckelbaum
-
Publication number: 20010003744Abstract: The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.Type: ApplicationFiled: December 14, 2000Publication date: June 14, 2001Inventors: Stanley Dawes Chamberlain, Susan Mary Daluge, George Walter Koszalka
-
Patent number: 6200961Abstract: A low volatile organic compound co-solvent system is disclosed for preparing emulsion concentrates of low melting organophosphorous insecticides wherein the bioefficacy of the insecticide active is significantly enhanced. The co-solvent system comprises a water-soluble ethoxylated fatty acid/rosin acid-nonionic surfactant composition.Type: GrantFiled: December 16, 1998Date of Patent: March 13, 2001Assignee: Aquatrols Corporation of America, Inc.Inventors: Stanley J. Kostka, Rennan Pan
-
Patent number: 6201002Abstract: Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.Type: GrantFiled: January 6, 1998Date of Patent: March 13, 2001Assignee: Merck & Co., Inc.Inventors: Polly A. Beere, Paul I. Chang, Bertram Pitt, Eva J. Rucinska, Robert Segal, Divakar Sharma, Duane B. Snavely
-
Patent number: 6187752Abstract: A method is provided for treating schizophrenia in a mammalian species by administering an ACE inhibitor, such as captopril, alone or with a neuroleptic such as cholecystokinin, fluphenazine or haloperidol.Type: GrantFiled: September 12, 1991Date of Patent: February 13, 2001Assignee: E.R. Squibb & Sons, Inc.Inventors: Abraham Sudilovsky, Joram Feldon, Ina Weiner, A. David Smith, John N. P. Rawlins